CIRCIO HOLDING ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.7 NOK | +0.75% |
|
-6.90% | -62.50% |
| Apr. 25 | Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 17 | Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform | MT |
Presenter SpeechLubor Gaal (Executives)Hello. Welcome to the First Half Report and Presentatio...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circioâs second clinical program is an immunotherapy targeting KRAS driver mutations.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.7
NOK
Average target price
48
NOK
Spread / Average Target
+1,677.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -62.50% | 1.86M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TRVX Stock
- News Circio Holding ASA
- Transcript : Circio Holding ASA, H1 2023 Earnings Call, Aug 24, 2023
